Doxironide magnetic nanoparticles for selective drug delivery to human acute myeloid leukemia

LAUR Repository

Show simple item record

dc.contributor.author Abi-Habib, Ralph
dc.contributor.author Azar, Daniel
dc.contributor.author El-Boubbou, Kheireddine
dc.contributor.author Bekdash, Amira
dc.date.accessioned 2018-06-13T08:45:34Z
dc.date.available 2018-06-13T08:45:34Z
dc.date.copyright 2017 en_US
dc.date.issued 2018-06-13
dc.identifier.issn 1550-7041 en_US
dc.identifier.uri http://hdl.handle.net/10725/8037
dc.description.abstract We report the development of a chemotherapeutic formulation made of polymeric-stabilized multifunctional magnetic metal oxide nanoparticles (M3NPs) of ferrites loaded with the anticancer drug Doxorubicin (Dox) as a promising drug carrier to AML. Loading efficiencies and release rates of the prepared NPs were thoroughly investigated. Using M3NP-drug conjugates (denoted as Doxironide), nanoparticulate uptake and cell death were evaluated in four different types of human AML target cells: ML-2, HL-60, Mono-Mac-1, and TF1-vRaf, as well as on normal human SVG-p12 cells. While the unloaded NPs were not toxic to any of the cells, Doxironide was found to be highly potent to the four AML cell lines, albeit at different inhibition concentrations (IC50 ranging from 0.48 to 4.8 μM Dox). Interestingly, and superior to free Dox, Doxironide was found to be more effective in killing the AML cells compared to the human normal cells (∼40× fold), suggesting huge potentials as selective AML anticancer agents. Electron, flow, and live confocal microscopy imaging mechanistically confirmed that the NPs were successfully uptaken, endocytosed and packaged into vesicles inside the cytoplasm, where Dox is released and then translocated to the nucleus exerting its cytotoxic action and causing apoptotic cell death. Importantly, this selective payload may potentially enhance the efficacy of drugs in AML patients and may further allow physicians to image leukemic cells exposed to Doxironide, opening new opportunities for in vivo AML theranostics. en_US
dc.language.iso en en_US
dc.title Doxironide magnetic nanoparticles for selective drug delivery to human acute myeloid leukemia en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SAS en_US
dc.author.idnumber 200901419 en_US
dc.author.department Natural Sciences en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Biomedical Nanotechnology, en_US
dc.journal.volume 13 en_US
dc.journal.issue 5 en_US
dc.article.pages 500-512 en_US
dc.keywords Acute myeloid leukemia en_US
dc.keywords Cancer en_US
dc.keywords Drug delivery en_US
dc.keywords Magnetic nanoparticles en_US
dc.keywords Metal oxide en_US
dc.identifier.doi https://doi.org/10.1166/jbn.2017.2365 en_US
dc.identifier.ctation El-Boubbou, K., Azar, D., Bekdash, A., & Abi-Habib, R. J. (2017). Doxironide Magnetic Nanoparticles for Selective Drug Delivery to Human Acute Myeloid Leukemia. Journal of Biomedical Nanotechnology, 13(5), 500-512. en_US
dc.author.email ralph.abihabib@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://www.ingentaconnect.com/content/asp/jbn/2017/00000013/00000005/art00003 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account